Interleukin-12 gene therapy in combination with bevacizumab and pegylated liposomal doxorubicin for treatment of disseminated ovarian cancer

被引：0
|
作者：
Fewell, Jason G.
Matar, Majed M.
Rice, Jennifer
McClure, Diane
Brunhoeber, Elaine
Sparks, Jeff
Greenleaf, Stefanie
Smith, Kelley
Anwer, Khursheed
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-2078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2078
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
    Newhouse, Rebecca
    Nelissen, Ellen
    El-Shakankery, Karim Hussien
    Rogozinsk, Ewelina
    Bain, Esme
    Veiga, Susana
    Morrison, Jo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (07):
  • [22] Pegylated liposomal doxorubicin (Caelyx™) in recurrent ovarian cancer
    Stebbing, J
    Gaya, A
    CANCER TREATMENT REVIEWS, 2002, 28 (02) : 121 - 125
  • [23] Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
    Yuan, Zhen
    Zhang, Ying
    Cao, Dongyan
    Shen, Keng
    Li, Qingshui
    Zhang, Guonan
    Wu, Xiaohua
    Cui, Manhua
    Yue, Ying
    Cheng, Wenjun
    Wang, Li
    Qu, Pengpeng
    Tao, Guangshi
    Hou, Jianqing
    Sun, Lixin
    Meng, Yuanguang
    Li, Guiling
    Li, Changzhong
    Shi, Huirong
    Chen, Yaqing
    JOURNAL OF OVARIAN RESEARCH, 2021, 14 (01)
  • [24] Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
    Lawrie, Theresa A.
    Bryant, Andrew
    Cameron, Alison
    Gray, Emma
    Morrison, Jo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (07):
  • [25] Long Term Combination Treatment With Bevacizumab, Pegylated Liposomal Doxorubicin and Regional Abdominal Hyperthermia in Platinum Refractory Ovarian Cancer: A Case Report and Review of the Literature
    Pietzner, Klaus
    Schmuck, Rosa Bianca
    Fotopoulou, Christina
    Gellermann, Johanna
    Ismaeel, Fakher
    Cho, Chie Hee
    Kalden, Michael
    Sehouli, Jalid
    ANTICANCER RESEARCH, 2011, 31 (08) : 2675 - 2677
  • [26] Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer
    Vergote, Ignace
    Finkler, Neil J.
    Hall, James B.
    Melnyk, Ostap
    Edwards, Robert P.
    Jones, Marsha
    Keck, James G.
    Meng, Lisa
    Brown, Gail L.
    Rankin, Elaine M.
    Burke, James J.
    Boccia, Ralph V.
    Runowicz, Carolyn D.
    Rose, Peter G.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (05) : 772 - 780
  • [27] Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis
    Lorusso, Domenica
    Sabatucci, Ilaria
    Maltese, Giuseppa
    Lepori, Stefano
    Tripodi, Elisa
    Bogani, Giorgio
    Raspagliesi, Francesco
    TUMORI JOURNAL, 2019, 105 (04): : 282 - 287
  • [28] Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer
    Lawrie, Theresa A.
    Rabbie, Roy
    Thoma, Clemens
    Morrison, Jo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (10):
  • [29] Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers
    Kudoh, Kazuya
    Takano, Masashi
    Kouta, Hiroko
    Kikuchi, Ryoko
    Kita, Tsunekazu
    Miyamoto, Morikazu
    Watanabe, Akio
    Kato, Masafumi
    Goto, Tomoko
    Kikuchi, Yoshihiro
    GYNECOLOGIC ONCOLOGY, 2011, 122 (02) : 233 - 237
  • [30] Effects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancer
    Kikuchi, Y., Sr.
    Kouta, H.
    Kikuchi, R.
    Takano, M.
    Kita, T.
    Kudoh, K.
    Aoki, D.
    Sugiyama, T.
    Isonishi, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345